The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial. / Bundgaard, Johan S.; Iversen, Kasper; Pries-Heje, Mia; Ihlemann, Nikolaj; Bak, Theis S.; Østergaard, Lauge; Gill, Sabine U.; Madsen, Trine; Elming, Hanne; Jensen, Kaare T.; Bruun, Niels E.; Høfsten, Dan E.; Fuursted, Kurt; Christensen, Jens J.; Schultz, Martin; Rosenvinge, Flemming; Schønheyder, Henrik C.; Helweg-Larsen, Jannik; Køber, Lars; Torp-Pedersen, Christian; Fosbøl, Emil L.; Tønder, Niels; Moser, Claus; Bundgaard, Henning; Mogensen, Ulrik M.
I: Journal of Psychosomatic Research, Bind 154, 110718, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The impact of partial-oral endocarditis treatment on anxiety and depression in the POET trial
AU - Bundgaard, Johan S.
AU - Iversen, Kasper
AU - Pries-Heje, Mia
AU - Ihlemann, Nikolaj
AU - Bak, Theis S.
AU - Østergaard, Lauge
AU - Gill, Sabine U.
AU - Madsen, Trine
AU - Elming, Hanne
AU - Jensen, Kaare T.
AU - Bruun, Niels E.
AU - Høfsten, Dan E.
AU - Fuursted, Kurt
AU - Christensen, Jens J.
AU - Schultz, Martin
AU - Rosenvinge, Flemming
AU - Schønheyder, Henrik C.
AU - Helweg-Larsen, Jannik
AU - Køber, Lars
AU - Torp-Pedersen, Christian
AU - Fosbøl, Emil L.
AU - Tønder, Niels
AU - Moser, Claus
AU - Bundgaard, Henning
AU - Mogensen, Ulrik M.
N1 - Publisher Copyright: © 2022 Elsevier Inc.
PY - 2022
Y1 - 2022
N2 - Background: The Partial-Oral versus Intravenous Antibiotic Treatment of Endocarditis Trial (POET) found that partial-oral outpatient treatment was non-inferior to conventional in-hospital intravenous treatment in patients with left-sided infective endocarditis. We examined the impact of treatment strategy on levels of anxiety and depression. Methods: Patients completed the Hospital Anxiety and Depression Scale (HADS) at randomization, at antibiotic completion, and after month 3 and month 6. Changes in anxiety and depression (each subdimension 0–21, high scores indicating worse) were calculated using a repeated measure analysis of covariance model with primary assessment after 6 months. Change in score of 1.7 represented a minimal clinical important difference (MCID). Results: Among the 400 patients enrolled in the POET trial, 263 (66%) completed HADS at randomization with reassessment rates of 86–87% at the three subsequent timepoints. Patients in the partial-oral group and the intravenous group had similar improvements after 6 months in levels of anxiety (−1.8 versus −1.6, P = 0.62) and depression (−2.1 versus −1.9, P = 0.63), although patients in the partial-oral group had numerically lower levels of anxiety and depression throughout. An improvement in MCID scores after 6 months was reported by 47% versus 45% (p = 0.80) patients for anxiety and by 51% versus 54% (p = 0.70) for depression. Conclusion: Patients with endocarditis receiving partial-oral outpatient treatment reported similar significant improvements in anxiety and depression at 6 months, as compared to conventionally treated, but numerically lower levels throughout. These findings support the usefulness of partial-oral treatment.
AB - Background: The Partial-Oral versus Intravenous Antibiotic Treatment of Endocarditis Trial (POET) found that partial-oral outpatient treatment was non-inferior to conventional in-hospital intravenous treatment in patients with left-sided infective endocarditis. We examined the impact of treatment strategy on levels of anxiety and depression. Methods: Patients completed the Hospital Anxiety and Depression Scale (HADS) at randomization, at antibiotic completion, and after month 3 and month 6. Changes in anxiety and depression (each subdimension 0–21, high scores indicating worse) were calculated using a repeated measure analysis of covariance model with primary assessment after 6 months. Change in score of 1.7 represented a minimal clinical important difference (MCID). Results: Among the 400 patients enrolled in the POET trial, 263 (66%) completed HADS at randomization with reassessment rates of 86–87% at the three subsequent timepoints. Patients in the partial-oral group and the intravenous group had similar improvements after 6 months in levels of anxiety (−1.8 versus −1.6, P = 0.62) and depression (−2.1 versus −1.9, P = 0.63), although patients in the partial-oral group had numerically lower levels of anxiety and depression throughout. An improvement in MCID scores after 6 months was reported by 47% versus 45% (p = 0.80) patients for anxiety and by 51% versus 54% (p = 0.70) for depression. Conclusion: Patients with endocarditis receiving partial-oral outpatient treatment reported similar significant improvements in anxiety and depression at 6 months, as compared to conventionally treated, but numerically lower levels throughout. These findings support the usefulness of partial-oral treatment.
KW - Antibiotic
KW - Anxiety
KW - Cardiovascular disease
KW - Depression
KW - Endocarditis
U2 - 10.1016/j.jpsychores.2022.110718
DO - 10.1016/j.jpsychores.2022.110718
M3 - Journal article
C2 - 35078079
AN - SCOPUS:85123194068
VL - 154
JO - Journal of Psychosomatic Research
JF - Journal of Psychosomatic Research
SN - 0022-3999
M1 - 110718
ER -
ID: 291221405